The importance of these mutations is highlighted in mutation carriers receiving chemotherapy, because HSCs carrying the truncated PPM1D show better survival and potentially may allow development of secondary cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome23,24. Here, PPM1D is linked to cancer.